Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | CTSV | O60911 | 4/20 | 0.58 |
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30082879 | 0.90 | MYC (0.59) | KMT2AMAPTMEN1ABCB1CTSV | |
| SCHEMBL527105 | 0.90 | MYC (0.59) | KMT2AMAPTMEN1ABCB1CTSV | |
| SCHEMBL11091089 | 0.89 | CTSV (0.57) | KMT2AMAPTMEN1ABCB1CTSV | |
| SCHEMBL8327970 | 0.88 | MAPT (0.53) | KMT2AMAPTMEN1ABCB1CTSV | |
| SCHEMBL5299658 | 0.88 | ABCB1 (0.55) | KMT2AMAPTMEN1ABCB1CTSV | |
| SCHEMBL13011586 | 0.87 | KMT2A (0.54) | KMT2AMAPTMEN1ABCB1CTSV | |
| SCHEMBL29368594 | 0.87 | ALDH1A1 (0.63) | KMT2AMAPTMEN1ABCB1CTSV | |
| SCHEMBL965943 | 0.87 | ALDH1A1 (0.63) | KMT2AMAPTMEN1ABCB1CTSV | |
| SCHEMBL750245 | 0.87 | CTSV (0.63) | KMT2AMAPTMEN1ABCB1CTSV | |
| SCHEMBL2722685 | 0.87 | MAPT (0.56) | KMT2AMAPTMEN1ABCB1CTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059219-A1 | LIGNAN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-02-20 | — | — | US | disclosed |
| CN-117440947-A | Lignan derivative, preparation method and application thereof | 中国科学院上海药物研究所 | 2024-01-23 | — | — | CN | disclosed |
| WO-2022222686-A1 | LIGNAN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2022-10-27 | — | — | WO | disclosed |
| CN-115215821-A | Lignan derivative, preparation method and application thereof | 中国科学院上海药物研究所 | 2022-10-21 | — | — | CN | disclosed |
| CN-110183348-B | N- (3-nitro-4-alkoxy benzoyl) amino acid compound, preparation method and application thereof | 中国医科大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-110183348-A | N- (3- nitro -4- alkoxybenzoyl) amino acids, preparation method and its usage | 中国医科大学 | 2019-08-30 | — | — | CN | disclosed |
| WO-2012053768-A2 | ARYLOXYPHENOXYACETYL-BASED COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-26 | — | — | WO | disclosed |
| EP-1996563-B1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2012-03-21 | — | — | EP | disclosed |
| US-8030308-B2 | Bicyclic sulfonamide derivatives which are L-CPT 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2011-02-24 | — | — | US | disclosed |
| US-7879845-B2 | Liver carnitine-dependent palmitoyltransferase (L-CPT1) inhibitors such as 4-{[4-(5-Chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbonyl]-amino}-benzoic acid, used for the treatment of non-insulin dependent diabetes; antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2010-05-27 | — | — | US | disclosed |
| US-7696200-B2 | Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1996563-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007093507-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059219-A1 | LIGNAN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | HADHA, HADHB, HADH | KMT2A 4107/4885MAPT 2828/4885MEN1 2640/4885 |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | KMT2A 2316/4885MAPT 3162/4885MEN1 4556/4885 |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | KMT2A 2316/4885MAPT 3162/4885MEN1 4556/4885 |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | KMT2A 2316/4885MAPT 3162/4885MEN1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.